<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493960</url>
  </required_header>
  <id_info>
    <org_study_id>CSUC-01/10</org_study_id>
    <secondary_id>2011-003130-14</secondary_id>
    <nct_id>NCT01493960</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients</brief_title>
  <acronym>COLLECT</acronym>
  <official_title>A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InDex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InDex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is
      effective in the treatment of chronic active ulcerative colitis patients not responding to
      available therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a placebo-controlled, double-blind, randomised study to assess the efficacy and
      safety of cobitolimod as an add-on to current practice in treatment refractory ulcerative
      colitis patients. The study population will be chronic active ulcerative colitis patients who
      are no longer responding adequately to standard therapies and who are potential candidates
      for colectomy. Cobitolimod/placebo will be add-on treatment allowing all included patients to
      be on concomitant medication, as well as mandatory steroids at inclusion, throughout the
      study.

      Cobitolimod (DIMS0150) is a modified single strand DNA-based synthetic
      oligodeoxyribonucleotide of 19 bases in length. The drug functions as an immunomodulatory
      agent by targeting the Toll-like receptor 9 (TLR9) present in immune cells (i.e., B-cells and
      pDCs) residing in high abundance on mucosal surfaces, such as colonic and nasal mucosa. The
      mucosa of the colon and rectum of patients with ulcerative colitis contains active immune
      cells, which produce damage to the tissue. The activation of these cells by cobitolimod
      results in the systemic release of specific cytokines (e.g., IL-10 and type I interferons)
      and chemokines which are believed to be important factors for the clinical effect cobitolimod
      of cobitolimod. 131 eligible patients was randomly assigned in a 2:1 allocation to receive
      two single rectal doses of cobitolimod at 30 mg each, or placebo, at week 0 and 4.

      The primary endpoint is the induction of clinical remission at week 12 and patients will be
      continuously followed for efficacy and safety until 12 months after the first dose. Secondary
      endpoints include the induction of symptomatic remission (number of stools and blood in
      stools), induction of registration remission (clinical and endoscopic remission) and rate of
      colectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction of Clinical Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>The induction of clinical remission at week 12, defined as a CAI score of ≤4.(Full Analysis Set)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time to Colectomy</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Median time to colectomy after 1st dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Colectomy</measure>
    <time_frame>at 12 months</time_frame>
    <description>Percentage of participants undergoing colectomy at 12 months after 1st dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid Free Remission at 12 Months</measure>
    <time_frame>at 12 months</time_frame>
    <description>Percentage of participants with steroid free remission at 12 months after 1st dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Induction of Mucosal Healing</measure>
    <time_frame>Week 4 and 12</time_frame>
    <description>Percentage of participants with induction of mucosal healing, defined as an endoscopic score of 0 or 1, at week 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Induction of Symptomatic Remission</measure>
    <time_frame>Week 4, 12</time_frame>
    <description>Percentage of participants with induction of symptomatic remission, defined as subscores of blood in stool and number of stools weekly not exceeding 0 and 0 or 1, respectively, at week 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Induction of Registration Remission</measure>
    <time_frame>Week 4 and 12</time_frame>
    <description>Percentage of participants with induction of registration remission, defined as a CAI score of ≤4 and an endoscopic score of 0 or 1, at week 4 and 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Cobitolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 doses 4 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobitolimod</intervention_name>
    <description>30 mg rectal dose at week 0 and 4</description>
    <arm_group_label>Cobitolimod</arm_group_label>
    <other_name>DIMS0150, Kappaproct</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Rectal dose at week 0 and 4</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age.

          2. Well established diagnosis of moderate to moderately severe chronic active UC with a
             CAI score ≥9, an endoscopic score ≥2, not responding adequately to currently available
             therapies and potential candidates for colectomy. Previously tried therapies should
             include:

               -  At least one treatment course with mesalazine; at least 2.4 g/day for at least 4
                  weeks, or at least one treatment course with similar drugs in this class.

               -  At least one full dose treatment course of corticosteroids (which can be the
                  treatment of a recent relapse), with up to 0.75 mg/kg as a starting dose or
                  highest dose according to local clinical practice.

               -  At least one treatment course of azathioprine or mercaptopurine of at least 3
                  months duration and/or at least one adequate treatment course of an anti-TNF
                  alpha.

               -  Any unsuccessful combination treatment of the above.

               -  May have tried treatment with cyclosporine and/or tacrolimus or any other
                  immunosuppressant/immunomodulating agent.

               -  Intolerance to any of the above medications is judged as inadequate response.

          3. Patients shall at study enrolment be on an accumulated stable tolerable GCS dose
             equivalent to at least 140 mg of prednisolone/prednisone (by any route of
             administration) for the last two weeks. Patients may also be on concomitant therapies
             such as, but not restricted to, 5-ASA, azathioprine and sulphasalazine.

          4. Ability to understand the treatment, willingness to comply with all study
             requirements, and ability to provide informed consent.

        Exclusion Criteria:

          1. Patients with suspicion of Crohn's enterocolitis, ischaemic colitis, radiation
             colitis, diverticular disease associated colitis, as well as microscopic colitis
             should be excluded. Patients with disease limited to the rectum (ulcerative proctitis)
             should also be excluded.

          2. History or presence of a clinically significant cardiovascular, hepatic, renal,
             haematological, endocrine, neurological, psychiatric disease, or immune compromised
             state as judged relevant by the investigator.

          3. Patients with acute fulminant UC and/or signs of systemic toxicity to an extent that
             requires immediate surgical action.

          4. History or presence of any colonic malignancy and/or dysplasia.

          5. Concomitant treatment with cyclosporine, tacrolimus, anti-TNFs or similar
             immunosuppressants/immunomodulators is not allowed and should have been discontinued 4
             weeks before enrolment. Patients who fail the wash-out criteria can undergo wash-out
             and be re-screened at a later time point. Ongoing treatment of anti-TNFs, tacrolimus
             or similar immunomodulators/immunosuppressant drugs should only be stopped in case of
             documented lack of efficacy or in case of intolerable side effects.

          6. Treatment with antibiotics or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within
             two weeks before enrolment.

          7. An active ongoing infection.

          8. History of latent or active tuberculosis, evidence of prior or currently active
             tuberculosis by chest x-ray, patient with or having had frequent close contact with
             person with active tuberculosis, patients who previously have tested positive for a
             tuberculin skin test, or Mantoux (PPD) test, except in the case of previous
             vaccination or positive interferon gamma release test during screening or within 12
             weeks prior to randomisation.

          9. Known history of HIV infection based on documented history with positive serology or
             HIV positive serology.

         10. Previously documented positive hepatitis B surface antigen determination,
             determination of total antibodies to the hepatitis B capsid antigen and/or hepatitis C
             antibody (HCVAb) with confirmation using the ribonucleic acid of hepatitis B virus.

         11. Positive Clostridium difficile stool assay.

         12. Currently receiving parenteral nutrition or blood transfusions.

         13. Pregnancy or breast-feeding.

         14. Women of childbearing potential not using reliable contraceptive methods (reliable
             methods are barrier protection, hormonal contraception, intra-uterine device or
             abstinence) throughout the duration of the study (52 weeks).

         15. Concurrent participation in another clinical study with investigational therapy or
             previous use of investigational therapy within 30 days before enrolment. Patients who
             fail the wash-out criteria can undergo wash-out and be re-screened at a later time
             point.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hawkey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham Digestive Diseases Centre, Queens Campus University Hospitals, Nottingham, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 404</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 406</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 407</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 405</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 409</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 403</name>
      <address>
        <city>Slaný</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 702</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 501</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 508</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 514</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 510</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 509</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 504</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 511</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 503</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 507</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 502</name>
      <address>
        <city>Stade</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 513</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 204</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 207</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 205</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 302</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 304</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 604</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 605</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 607</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 606</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 601</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 602</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 603</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>June 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2018</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colitis, Ulcerative</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Immunomodulatory Therapy</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Therapeutic uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 162 subjects screened. Whereof 31 did not meet the criteria</recruitment_details>
      <pre_assignment_details>There were131 patients randomly assigned in a 2:1 allocation to receive 2 rectal doses of cobitolimod at 30 mg, or placebo, respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cobitolimod</title>
          <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS</population>
      <group_list>
        <group group_id="B1">
          <title>Cobitolimod</title>
          <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="13.88"/>
                    <measurement group_id="B2" value="43.1" spread="12.31"/>
                    <measurement group_id="B3" value="41.8" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Summary of CAI score at baseline by treatment group</title>
          <description>Clinical Activity Index (CAI) which consists of a 7 item scale CAi score is a summary score ranging from 0-29 The summary score indicates increasing values with worsening symptoms</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="2.2"/>
                    <measurement group_id="B2" value="10.8" spread="2.1"/>
                    <measurement group_id="B3" value="11.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction of Clinical Remission</title>
        <description>The induction of clinical remission at week 12, defined as a CAI score of ≤4.(Full Analysis Set)</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS consited of all randomized patients who met the inclusion criteria (as assessed by the investigator on the inclusion/exclusion criteria form), and received at least 1 dose of study drug (active or placebo), and who had at least 1 post randomization eligible value of the primary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Induction of Clinical Remission</title>
          <description>The induction of clinical remission at week 12, defined as a CAI score of ≤4.(Full Analysis Set)</description>
          <population>The FAS consited of all randomized patients who met the inclusion criteria (as assessed by the investigator on the inclusion/exclusion criteria form), and received at least 1 dose of study drug (active or placebo), and who had at least 1 post randomization eligible value of the primary efficacy endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="34.1" upper_limit="55.3"/>
                    <measurement group_id="O2" value="46.5" lower_limit="32.5" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Colectomy</title>
        <description>Median time to colectomy after 1st dose.</description>
        <time_frame>Within 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Colectomy</title>
          <description>Median time to colectomy after 1st dose.</description>
          <population>FAS</population>
          <units>Time</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median was not reached due to few events</measurement>
                    <measurement group_id="O2" value="NA">Median was not reached due to few events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Colectomy</title>
        <description>Percentage of participants undergoing colectomy at 12 months after 1st dose.</description>
        <time_frame>at 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Colectomy</title>
          <description>Percentage of participants undergoing colectomy at 12 months after 1st dose.</description>
          <population>FAS</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="1.9" upper_limit="12.0"/>
                    <measurement group_id="O2" value="11.6" lower_limit="5.1" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid Free Remission at 12 Months</title>
        <description>Percentage of participants with steroid free remission at 12 months after 1st dose.</description>
        <time_frame>at 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Free Remission at 12 Months</title>
          <description>Percentage of participants with steroid free remission at 12 months after 1st dose.</description>
          <population>FAS</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="22.9" upper_limit="42.9"/>
                    <measurement group_id="O2" value="30.2" lower_limit="18.6" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Induction of Mucosal Healing</title>
        <description>Percentage of participants with induction of mucosal healing, defined as an endoscopic score of 0 or 1, at week 4 and 12.</description>
        <time_frame>Week 4 and 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>The Induction of Mucosal Healing</title>
          <description>Percentage of participants with induction of mucosal healing, defined as an endoscopic score of 0 or 1, at week 4 and 12.</description>
          <population>FAS</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="25.1" upper_limit="45.4"/>
                    <measurement group_id="O2" value="18.6" lower_limit="9.7" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="31.8" upper_limit="52.8"/>
                    <measurement group_id="O2" value="41.9" lower_limit="28.4" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Induction of Symptomatic Remission</title>
        <description>Percentage of participants with induction of symptomatic remission, defined as subscores of blood in stool and number of stools weekly not exceeding 0 and 0 or 1, respectively, at week 4 and 12.</description>
        <time_frame>Week 4, 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>The Induction of Symptomatic Remission</title>
          <description>Percentage of participants with induction of symptomatic remission, defined as subscores of blood in stool and number of stools weekly not exceeding 0 and 0 or 1, respectively, at week 4 and 12.</description>
          <population>FAS</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="22.9" upper_limit="42.9"/>
                    <measurement group_id="O2" value="14.0" lower_limit="6.6" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="33.0" upper_limit="54.1"/>
                    <measurement group_id="O2" value="32.6" lower_limit="20.5" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Induction of Registration Remission</title>
        <description>Percentage of participants with induction of registration remission, defined as a CAI score of ≤4 and an endoscopic score of 0 or 1, at week 4 and 12.</description>
        <time_frame>Week 4 and 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cobitolimod</title>
            <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>The Induction of Registration Remission</title>
          <description>Percentage of participants with induction of registration remission, defined as a CAI score of ≤4 and an endoscopic score of 0 or 1, at week 4 and 12.</description>
          <population>FAS</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="13.5" upper_limit="31.1"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.3" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="21.9" upper_limit="41.6"/>
                    <measurement group_id="O2" value="30.2" lower_limit="18.6" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 2 weeks</time_frame>
      <desc>All patients who entered into the study and were treated with at least 1 dose of study drug are included in the safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cobitolimod</title>
          <description>2 doses 4 weeks apart
Cobitolimod: 30 mg rectal dose at week 0 and 4</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 doses 4 weeks apart
Placebo: Rectal dose at week 0 and 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myocardial Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Retinal Veon Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Distrurbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Benign Dysplaisa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDra 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Thomas Knittel</name_or_title>
      <organization>Index Pharmaceuticals</organization>
      <phone>0046 8 508 847 31</phone>
      <email>thomas.knittel@indexpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

